Intravenous Allopurinol in Heart Failure

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• Age > 18 years

• The patient is willing and able to provide informed consent

• Clinical diagnosis of chronic heart failure

• Ejection fraction (EF) < 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography

• No significant coronary disease at cardiac catheterization

• New York Heart Association (NYHA) Class I-IV symptoms

• Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.

Exclusion Criteria:

• Metallic implant prohibiting magnetic resonance (MR) evaluation

• Inability to lie flat for MR study

• Administration of additional investigational drugs

• Calculated creatinine clearance < 50 mL/min

• Allergy to allopurinol

• Current gout flare

• Currently taking oral allopurinol